Kronos mulls 'strategic alternatives' after axing cancer drug development

By Yahoo! Finance | Nov 14, 2024 at 01:30 PM EST

Kronos Bio has halted the development of istisociclib due to safety concerns from a clinical trial. Facing financial challenges, the company plans to explore strategic options and partnerships for its remaining assets, including KAT inhibitors for cancer and autoimmune disorders.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.